Saphnelo Wins FDA Approval as At-Home Injection for Lupus

The U.S. Food and Drug Administration (FDA) has approved a new, more flexible way to take Saphnelo (anifrolumab-fnia) for people living with systemic lupus erythematosus (SLE). The therapy is now available as a once-weekly autoinjector, called the Saphnelo Pen, allowing patients to self-administer treatment at home instead of receiving it through an IV infusion in a clinic.

This approval marks an important step forward in lupus care, offering patients greater convenience and control over how they manage their condition.

“The approval of anifrolumab as a self-administered autoinjector is exciting news, as it makes this important medicine more convenient and accessible for many more patients,” said the lead investigator of the TULIP-SC trial, Susan Manzi, M.D., M.P.H., chair of the Allegheny Health Network (AHN) Medicine Institute and director of the Lupus Center of Excellence at the AHN Autoimmunity Institute. “With its proven ability to significantly reduce disease activity and the risk of organ damage, anifrolumab has been a much-needed innovation in lupus, which is a serious and often debilitating autoimmune condition impacting millions worldwide.”

What Is Saphnelo and How Does It Work?

Saphnelo is a first-in-class biologic therapy, meaning it works differently from traditional lupus treatments. It targets a key pathway in the immune system known as the Type 1 interferon pathway, which plays a major role in inflammation in lupus. By blocking this pathway, Saphnelo helps reduce disease activity and prevent flares.

Unlike commonly used treatments such as corticosteroids, which can have significant long-term side effects, Saphnelo is designed to address one of the underlying drivers of lupus.

What the Research Showed

The FDA approval of the self-injectable version is based on results from the Phase III TULIP-SC clinical trial, published in Arthritis & Rheumatology earlier this year. In this study, patients with moderate to severe lupus who added Saphnelo to standard treatment experienced meaningful improvements.

Key findings included the following:

• Reduced disease activity compared with placebo
• Faster and more frequent treatment responses
• More patients reaching low disease activity or remission
• Ability to lower steroid use, which is a major goal in lupus care

At one year:

• 29% of patients achieved remission
• Over 40% reached low disease activity

These results are especially important because lupus is a complex, chronic disease that can affect multiple organs and significantly impact quality of life.

Why the Autoinjector Matters

Until now, Saphnelo has been available only as an IV infusion administered in a health care setting. The new autoinjector changes that by allowing patients to take their medication at home. Benefits for patients include greater convenience and flexibility, fewer clinic visits and more independence in managing treatment. This can be especially meaningful for patients balancing work, family and ongoing medical care.

Safety and Side Effects

The safety profile of the injectable version is consistent with the IV form. The most common side effects include upper respiratory infections, bronchitis, cough, herpes zoster (shingles) and mild injection-related reactions like headache or fatigue

Why This Approval Matters

Lupus affects more than 3 million people worldwide and is a leading cause of death among young women in the U.S. The disease disproportionately impacts Black, Hispanic and Asian populations and often requires long-term treatment.

This approval reflects a broader shift in lupus care toward the following:

• Reducing reliance on steroids
• Targeting the root causes of disease
• Giving patients more choice in how they receive treatment

By offering a self-injection option, Saphnelo may help more patients access and stay on effective therapy — potentially improving long-term outcomes.

“The FDA approval of a subcutaneous administration option for anifrolumab is an exciting milestone for the lupus community because it offers people with systemic lupus erythematosus more convenience and choice of where and how they want to receive treatment,” said Louise Vetter, president and chief executive officer of the Lupus Foundation of America.